Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Is microchimerism a sign of imminent disease recurrence after allogeneic hematopoietic stem cell transplantation? A systematic review of the literature

Publikation: Bidrag til tidsskriftReviewpeer review

DOI

  1. Cost-effectiveness targeting CLL

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Novel manifestations of immune dysregulation and granule defects in gray platelet syndrome

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Sirolimus with CSP and MMF as GVHD prophylaxis for allogeneic transplantation with HLA antigen-mismatched donors

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Effects of germline DHFR and FPGS variants on methotrexate metabolism and relapse of leukemia

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Human erythroleukemia genetics and transcriptomes identify master transcription factors as functional disease drivers

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Citrulline as a biomarker of bacteraemia during induction treatment for childhood acute lymphoblastic leukaemia

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Correction: ABO incompatibile graft management in pediatric transplantation

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Severe influenza in a paediatric patient with GATA2 deficiency and Emberger syndrome

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Chimerism analysis following hematopoietic stem cell transplantation (HSCT) for leukemia is routinely applied in parallel with quantification of minimal residual disease (MRD) to identify imminent relapse. In the past decades, new methods with a lower limit of detection compared to standard methods have been developed, so-called microchimerism analysis. Microchimerism analysis is fast, simple, applicable across pre-HSCT disease-type and can be applied on peripheral blood allowing frequent testing during follow-up. Monitoring of microchimerism in blood could replace repeated bone marrow analysis for MRD and allow earlier detection of imminent relapse or graft failure. Clinical studies in single center cohorts have shown conflicting but promising results. There is currently no consensus on the interpretation of microchimerism analysis and heterogeneity of studies remains a major obstacle for inter-study comparisons and meta-analysis in this field. We have conducted a systematic review of studies investigating associations between microchimerism and relapse of leukemia post-HSCT. We summarize current evidence and provide suggestions for future research.

OriginalsprogEngelsk
TidsskriftBlood
Vol/bind44
Sider (fra-til)100673
ISSN0006-4971
DOI
StatusUdgivet - nov. 2020

Bibliografisk note

Copyright © 2020 Elsevier Ltd. All rights reserved.

ID: 61695986